2023 Clinical Neuromuscular Pathology Reading List

Reading List

Please click below to access the 2023 Clinical Neuromuscular Pathology reading list.

2023 Clinical Neuromuscular Pathology Reading List »

C-cert Activity Description

The Continuous Certification (C-cert) activities provide subspecialty learning and knowledge assessment to ensure that diplomates are staying up to date on the latest science, treatments, and therapeutics relating to their subspecialty. The annual activities include: 1) reading the subspecialty  journal articles, and 2) taking and passing the 25-question online post-reading quiz to assess knowledge gained from the journal article content. 

Learning Objectives

Upon completion of this UCNS C-cert activity, participants will be able to:
  • Identify clinical and pathological correlates of neuromuscular disorders including the idiopathic inflammatory myopathies, dystrophies, amyloidosis, and systemic lupus erythematosus
  • Distinguish CIDP and its variants from CISP and CISP-Plus
  • Identify neuromuscular complications of vasculitis
  • Describe the pathologic features of genetic neuropathies
  • Discuss clinical histopathological features in muscle disorders in core disease


The UCNS complies with all standards and policies of the ACCME, including identification and resolution of all conflicts of interest prior to the educational activity being delivered to learners. Accordingly, UCNS  planners, authors, and staff comply with the UCNS’s Conflicts of Interest Policy

2023 C-cert Activity Planner Disclosures
All relevant financial relationships have been mitigated.

Clinical Neuromuscular Pathology Certification Examination Committee Contributors

Mazen Mohammad Dimachkie, MD, Chair, University of Kansas Medical Center
Disclosures: Serves or recently served as a consultant for Amazentis, ArgenX, Catalyst, Cello, Covance/Labcorp, CSL-Behring, EcoR1, Janssen, Kezar, Medlink, Momenta, NuFactor, Octapharma, RaPharma/UCB, Roivant Sciences Inc, Sanofi Genzyme, Shire Takeda, Scholar Rock, Spark Therapeutics, Abata/Third Rock, UCB Biopharma and UpToDate; DMC for Covance/LabCorp; received research grants or contracts or educational grants from Alexion, Alnylam Pharmaceuticals, Amicus, Biomarin, Bristol-Myers Squibb, Catalyst, Corbus, CSL-Behring, FDA/OOPD, GlaxoSmithKline, Genentech, Grifols, Kezar, Mitsubishi Tanabe Pharma, MDA, NIH, Novartis, Octapharma, Orphazyme, Ra Pharma/UCB, Sanofi Genzyme, Sarepta Therapeutics, Shire Takeda, Spark Therapeutics, The Myositis Association, UCB Biopharma / RaPharma, Viromed/Healixmith & TMA; received other compensation from Medlink and UpToDate.

Michelle Lynn Mauermann, MD, Vice Chair, Mayo Clinic – Rochester
Disclosures: Receives research support from Alnylam, IONIS, and EIDOS for amyloid clinical trials.

Rocio Carolina Garcia Santibanez, MD, Emory Brain Health Center
Disclosures: Nothing to disclose.

Ahmed Mohamed Attia El-Dokla, MD, Neuromuscular Clinic at Upstate Bone & Joint
Disclosures: Nothing to disclose.

Shalini Mahajan, MD, Cedars-Sinai Medical Center
Disclosures: Nothing to disclose.

Raghav Govindarajan, MD, St. Elizabeth Medical Group, Illinois
Disclosures: Received compensation from Appellis pharma, DSMB chair; speakers bureau fees from Alexion Argenx; research support from MDA, ALSA, Alexion; royalties from Springer Cambridge. 

Margherita Milone, MD, PhD, Mayo Clinic – Rochester
Disclosures: Received compensation from AAN to serve as associate editor of Neurology Genetics; research support from Mayo Clinic.

Aziz Shaibani, MD, Nerve and Muscle Center of Texas
Disclosures: Nothing to disclose.

Anthony A. Amato, MD, Brigham and Women's Hospital
Disclosures: Received compensation from Teledoc/Best Doctors: provide second opinion on challenging cases; MAB/consultant for Ra Pharma, Horizon Pharmaceuticals, Abcuro, Argenx, EMD Serano, Orphazyme, Ono Pharma to discuss possible treatments for various neuromuscular disease and design of trials; Associate Editor of Neurology; reviewed medical records and provided deposition testimony on medical malpractice cases.

Mohamed Kazamel, MD, University of Alabama at Birmingham
Disclosures: Received compensation from Alnylam Pharmaceuticals for consulting service.

Staff Contact

Bryan Hagerla, Continuous Certification Manager
Disclosures: Nothing to disclose.
[email protected]
(612) 928-6326